Search clinical trials for: Apalutamide

Total 112 results

Mayo Clinic

Not yet recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
University of Washington
Washington State University

Not yet recruiting

Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 (OralT12)

Hypogonadism, Male
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC

Not yet recruiting

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Prostate Cancer | Prostatectomy | Androgen Axis Suppression

United States
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Not yet recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
Royal Marsden NHS Foundation Trust
Janssen, LP

Recruiting

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients (ADAPT-P)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United Kingdom
University of Washington
Janssen Scientific Affairs, LLC

Recruiting

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, Austria, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS)

Metastatic Castrate-sensitive Prostate Cancer

United States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
Sumitomo Pharma Switzerland GmbH

Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Endometriosis | Uterine Fibroids

United States
Novartis Pharmaceuticals

Recruiting

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare)

Prostatic Neoplasm

Korea, Republic of, Singapore, United States, Canada, Poland, Spain, Czechia
University of Cincinnati
Janssen, LP

Recruiting

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Xian-Janssen Pharmaceutical Ltd.

Not yet recruiting

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) (ARES)

Prostate Cancer | Biochemical Recurrence | High Risk

China
H. Lee Moffitt Cancer Center and Research Institute
Dendreon

Recruiting

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer

United States
Zhujiang Hospital

Recruiting

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

Prostate Cancer With ≤10 Bone Metastases

China
Fudan University

Not yet recruiting

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment (CHAMPION)

Metastatic Prostate Cancer | Castration-Sensitive Prostate Cancer

China
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer (PERSIAN)

Oligometastatic Hormone Sensitive Prostate Cancer

Italy
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Recruiting

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
European Institute of Oncology; ASST Santi Paolo e Carlo

Recruiting

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment (APPROACH)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Italy
UNC Lineberger Comprehensive Cancer Center

Recruiting

Physical Function During ARSI Treatment

Advanced Prostate Carcinoma

United States
Edwin Posadas, MD
Enviro Therapeutics, Inc.

Recruiting

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
James J. Peters Veterans Affairs Medical Center

Not yet recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Metastatic Cancer | Neoplasm, Prostate

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine Therapy

China
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
Fudan University

Recruiting

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Prostate Cancer

China
Instituto de Investigación en Oncología Radioterápica...
Instituto de Investigación en Oncología Radioterápica FEOR (IRAD-FEOR)

Recruiting

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC (START-MET)

Prostate Cancer | Stereotactic Body Radiation Therapy

Spain
Helsinki University Central Hospital
University of Helsinki

Recruiting

Evaluation of Fapi-pet in Prostate Cancer. (FAPIPETPCA)

Prostate Cancer

Finland
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge; Janssen-Cilag Ltd.

Recruiting

TherApeutics in Early ProState Cancer (TAPS02)

Prostate Cancer

United Kingdom
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
Zhujiang Hospital

Recruiting

An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

High-Risk and Oligometastatic Prostate Cancer

China
M.D. Anderson Cancer Center

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
University of British Columbia
University Health Network, Toronto; Janssen Inc.

Recruiting

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS)

Prostate Cancer

Canada, United States
VA Office of Research and Development

Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT)

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Oligometastasis | Oligorecurrence | De Novo Prostate Cancer

United States
Myovant Sciences GmbH

Recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
Kindai University
Janssen Pharmaceutical K.K.

Recruiting

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan (CUARTET)

Metastatic Castration-sensitive Prostate Cancer

Japan
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Belgium, United States, Italy, Poland, Brazil, Denmark, Germany, Hungary, Mexico, Portugal, Russian Federation, Spain, Sweden, Turkey, Czechia, Finland, Austria, Australia, Lebanon, Slovakia, Jordan
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
ESSA Pharmaceuticals

Recruiting

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer (EPI-7386)

Prostate Cancer

United States, Canada
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Westfälische Wilhelms-Universität Münster
Janssen Pharmaceutica N.V., Belgium

Recruiting

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM)

Prostatic Neoplasms

Austria, Germany
UNICANCER
Janssen Pharmaceutica

Recruiting

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2)

Prostate Cancer

France
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditions

United States
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Cancer Research Antwerp
Janssen Pharmaceutica

Recruiting

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE)

Cancer of Prostate

Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
Rahul Aggarwal
Janssen Scientific Affairs, LLC

Active, not recruiting

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Prostate Cancer | Small Cell Carcinoma | Small Cell Neuroendocrine Carcinoma

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

Prostatic Neoplasms

United States, Australia, France, Poland, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Romania, Japan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Hungary, Austria, Sweden, Slovaki... and more

Search clinical trials for: Apalutamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations